SUMMARY Sm antigen was purified by immunoaffinity chromatography using a murine monoclonal anti-Sm antibody and was confirmed to be free from contaminating polypeptides. This was then used to detect anti-Sm antibodies in patients' sera by enzyme linked immunosorbent assay (ELISA). Antibodies Later studies showed that the Sm antigen could be separated from the RNP/Sm complex by affinity chromatography.4 The advent of murine monoclonal anti-Sm antibodies led to the adaptation of this technique to enable characterisation of the RNA and protein components of the Sm antigen.5 Immunoblotting analysis with these antibodies6 has
confirmed that the antigenic determinants reside on the protein moieties.
The aim of this study was to use a murine monoclonal anti-Sm antibody to obtain highly purified Sm antigen by affinity chromatography for use in an ELISA. Serum samples from patients with autoimmune diseases were analysed for the presence of anti-Sm antibodies to investigate their diagnostic specificity for SLE. The clinical features of all patients were analysed to assess whether the presence of anti-Sm antibodies predisposes to any specific disease manifestations.
The soluble fraction was initially applied to a column made with normal human IgG, and the drop through was sequentially passed down a column containing IgG from a patient with high titre monospecific anti-RNP antibody and then down the column made with the murine monoclonal anti-Sm antibody (KSm2). Each column was separated, washed, and eluted with 3 M guanidinium hydrochloride (Sigma, Poole, Dorset). Fractions with the highest optical density at 280 nm were pooled, dialysed against phosphate buffered saline (PBS), and stored at 0°C. Each extraction yielded 1-1 5 mg of pure Sm antigen from 2 g of rabbit thymus extract.
POLYPEPTIDE ANALYSIS
The purified protein antigens were analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)7 modified according to Williams et al.6 The separated proteins were stained with Coomassie blue (Fig. 1) .
The Sm antigen was also screened by ELISA (which see) using two murine monoclonal antibodies6 directed against the 29, 28 kilodalton doublet (KSm5) or the 16 kilodalton (KSm2) components of the Sm antigen to ensure both proteins were present in the purified antigen. The optical density of each sample was compared with a standard curve obtained by diluting a monospecific serum containing a high titre of anti-Sm antibodies. This was diluted threefold from 1:100 to 1:24 300 on each plate (Fig. 2) . The lowest optical density obtained for a dilution of 1:24 300 was arbitrarily allocated a value of 3 ELISA units, that for the dilution of 1:8100-9 units, increasing up the dilution scale so that the value for the 1:300 dilution was ascribed 243 units. For those serum samples producing results above the standard curve a dilution was made and appropriate correction calculated to obtain the result for the standard dilution. All results were compared with those obtained in the laboratory by routine immunodiffusion. kilodalton Sm polypeptides but also contained many contaminating bands (Fig. 1, lane 3) . (Fig. 4) renal biopsy was graded,10 however, the presence of anti-Sm antibodies was negatively associated with a pure diffuse proliferative glomerulonephritis (p<005) and positively associated with a membranous component to the glomerulonephritis (p<0-05) ( Table 2) .
Discussion
These data demonstrate that immunoaffinity chromatography with monoclonal antibodies produces large quantities of Sm antigen without significant In an ELISA study for anti-Sm antibodies Maddison et al immunopurified Sm from RNAse digested thymus extract using human polyclonal antisera.14 Anti-Sm antibodies were detected in patients with SLE but also in those with rheumatoid arthritis and other autoimmune diseases. Our data show that extraction by human polyclonal antisera leads to copurification of non-specifically bound proteins (Fig. 1) , which could result in false positive tests.
These data demonstrate that the disease specificity of anti-Sm antibodies for SLE in sensitive ELISA assays depends on antigenic purity.
Pollard and Tan used biochemically purified antigen in an ELISA and found anti-Sm antibodies restricted to patients with SLE, but also in one patient with diabetes mellitus and a facial rash.'5 The use of the monoclonal antibody to purify Sm antigen by affinity chromatography produces larger quantities of pure Sm than biochemical techniques, and its use in the ELISA shows that only patients with SLE have detectable IgG anti-Sm antibodies. Thus this method will provide an assay which could be readily used in clinical practice.
Comparison of ELISA and immunodiffusion showed six samples positive for anti-Sm by ELISA which were negative by immunodiffusion. Of these, four had anti-Sm antibodies in their serum detected by immunodiffusion either in previous or subsequent samples, implying that the ELISA is more sensitive than immunodiffusion. All four samples also had detectable anti-RNP antibodies by immunodiffusion, which may obscure anti-Sm precipitins.
Early studies suggested a link between anti-Sm antibodies and cerebral SLE,17 though these antibodies were not confirmed as markers for central nervous system disease in the lupus population as a whole. 24 and the 17% in the Indian population25 and are more in line with the prevalence in the USA lupus population.26 Nevertheless, the wide racial difference in the incidence of anti-Sm antibodies has been confirmed. 23 Whether this is the result of genetic differences or the effect of some environmental factor in the initiation of the anti-Sm antibody response remains to be understood. 
